March 10, 2009
ADXS11-001 for orphan drug designationAdvaxis submitted ADXS11-001 (formerly known as Lovaxin-C) to the FDA for orphan drug designation to treat invasive carcinoma of the cervix. The company's technology platform uses modified Listeria monocytogenes to deliver a tumor-specific antigen fusion protein.
ADXS11-001 is a therapeutic vaccine that treats women who have already developed cervical cancer as a result of human papilloma virus (HPV) infection.
For more information visit www.advaxis.com.